Tag Archive for: Cancer

Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform

/in

Adcendo licenses Duality’s DITAC (Duality Immune Toxin Antibody Conjugates) linker/payload platform for its lead uPARAP-ADC program Agreement based on synergies between Adcendo and Duality in generating breakthrough ADCs in hard-to-treat cancers Copenhagen, Denmark, January 5, 2023 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of […]

Read more

ISA Pharmaceuticals and Cancer Focus Fund Announce $5 Million Investment to Support First-in-Human Trial of ISA’s Novel Immunotherapy ISA103 in Uveal Melanoma

/in

─Clinical Trial of PRAME-Targeting Immunotherapy ISA103 in rare ocular cancer to be conducted at MD Anderson Cancer Center─ Oegstgeest, Netherlands and Houston, Texas, January 4, 2023 – ISA Pharmaceuticals B.V., a clinical stage biotech company developing immunotherapies to treat cancers and infectious diseases, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with […]

Read more

STORM Therapeutics announces closing of USD $30M Series B financing

/in

Proceeds will advance STORM’s potential first-in-class clinical program targeting METTL3 for treatment of solid tumors and leukemias  Financing will further expand STORM’s novel discovery platform to create additional products targeting RNA modification 14 December 2022, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying […]

Read more

Another Award for Synaffix: ‘Business Development Team of Year’ at the Scrip Awards

/in

AMSTERDAM, THE NETHERLANDS, December 13, 2022 – Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that the Company has been awarded ‘Business Development Team of Year’ at the annual Scrip Awards ceremony held on the 30th of November, at […]

Read more

CellCentric presents early clinical data at ASH

/in

Inobrodib (CCS1477), first in class p300/CBP bromodomain inhibitor treating relapsed refractory multiple myeloma Inobrodib is an oral drug showing good long-term tolerability at the recommended phase 2 dose as monotherapy Objective responses have been observed in heavily pre-treated relapsed/ refractory multiple myeloma patients Inobrodib is also being evaluated in combination with pomalidomide/ dexamethasone, with clear […]

Read more
© Optimum Strategic Communications.